Dynavax's on-hold hepatitis B vaccine succeeds in Phase III
This article was originally published in Scrip
Executive Summary
Dynavax Technologies'/Merck & Co's investigational hepatitis B vaccine Heplisav, which is currently on clinical hold, has met its primary endpoint in a Phase III non-inferiority trial comparing it with GlaxoSmithKline's currently marketed hepatitis B vaccine, Engerix-B.